牛皮患者的生物治疗的处方和切换模式:现实世界的经验
Chai Har Loo1, Suganthi Thevarajah2, Min Moon Tang2,3
1Department of Dermatology, Hospital Pulau Pinang, Georgetown, Penang, Malaysia.
Clinical and experimental dermatology
|November 11, 2025
概括
在马来西亚,有2.2%的牛皮患者使用生物治疗. 抗干白素-17 (抗IL17) 药物是最初和随后的生物治疗的首选选择.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 牛皮治疗景观随着新的生物药物而演变.
- 马来西亚已经看到银病患者的选择增加.
- 了解生物处方和切换模式至关重要.
研究的目的:
- 评估马来西亚的生物药物处方模式.
- 分析牛皮的生物药物之间的切换模式.
- 确定马来西亚牛皮患者生物治疗的趋势.
主要方法:
- 利用了来自马来西亚牛皮病登记 (MPR) (2011年1月 - 2022年9月) 的数据.
- 包括所有用生物制剂治疗的患者.
- 基于连续治疗和切换治疗定义的切换模式的子组分析.
主要成果:
- 25,468名患者中有2.2%接受了生物药物治疗;平均年龄为42.6岁.
- 塞库金纽马布是被处方最多的生物药物 (37.8%),其次是乌斯特基努马布 (27.9%).
- 14.4%的患者转换了生物药物,由于缺乏疗效,更喜欢抗IL17药物 (46.3%).
结论:
- 在马来西亚,抗干白素-17 (抗IL17) 药物是首选的一线和二线生物疗法.
- 生物治疗被少量但很大一部分牛皮患者使用.
- 缺乏疗效是切换在牛皮管理中的生物药物的主要驱动因素.
相关概念视频
Drug Therapy
226
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
226
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
Therapeutic Drug Monitoring: Affecting Factors
163
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
163
Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
Psychosis: Goals of Pharmacotherapy
434
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
434
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427


